Therapeutics | Most Viewed Papers in the First Half of 2025

As all of the articles published in Therapeutics (ISSN: 2813-9909) are of open access format, you have free and unlimited access to the full text of all articles. We invite you to read most viewed papers in the first half of 2025, which are listed below:

1. “Effects of Daratumumab (Anti-CD38) Monoclonal Antibody Therapy on Flow Cytometry Analysis in Multiple Myeloma”
by Sharon Koorse Germans, Christine Wamsley Kahlow, Weina Chen and Franklin Fuda
Therapeutics 2025, 2(1), 2; https://doi.org/10.3390/therapeutics2010002
Available online: https://www.mdpi.com/2813-9909/2/1/2

2. “Pharmacologic Management of Anticoagulation in Patients with Hepatic Cirrhosis: A Review of Dosing and Monitoring Strategies”
by Diane N. Gutgsell and Randolph E. Regal
Therapeutics 2025, 2(2), 8; https://doi.org/10.3390/therapeutics2020008
Available online: https://www.mdpi.com/2813-9909/2/2/8

3. “How Natural Therapies Can Combat Neoplastic Disease by Targeting Key Survival Mechanisms and Signaling Pathways”
by Simge Karagil, Aleksandra Szczesnowska, Natalia Haddad, Sara Magura Gamaethige, Ellen Coakley, Nabila Dawood, Vernard J. Rama, James Barker, Moses K. Langat, Huda Morgan et al.
Therapeutics 2025, 2(1), 5; https://doi.org/10.3390/therapeutics2010005
Available online: http://www.mdpi.com/2813-9909/2/1/5

4. “Examining Benefits and Limitations to Treatment Outcome Measurement Tools for Substance Use Disorder: A Scoping Review”
by Darian Peters, Jacob Kalathoor, Courtney Phillips, Belma Andric and Lea Sacca
Therapeutics 2025, 2(1), 3; https://doi.org/10.3390/therapeutics2010003
Available online: https://www.mdpi.com/2813-9909/2/1/3

5. “The Impact of Leptomeningeal Metastasis in Patients with Non-Small Cell Lung Cancer with EGFR Mutation: Survival Analysis of a Retrospective Cohort Study”
by Danilo Giffoni de Mello Morais Mata, Tatianny P. Araujo Vargas, Carlos Amir Carmona, Abdullah Al-Humiqani, Sara Gehlaut, Alia Thawer, Maria Romero, Mark K. Doherty and Ines B. Menjak
Therapeutics 2025, 2(2), 7; https://doi.org/10.3390/therapeutics2020007
Available online: https://www.mdpi.com/2813-9909/2/2/7

6. “The Golden Hamster: A Valuable Model for Designing Cancer Therapies”
by Mahmoud Singer, David K. Imagawa, Michael Alexander and Nadine Abi-Jaoudeh
Therapeutics 2025, 2(3), 10; https://doi.org/10.3390/therapeutics2030010
Available online: https://www.mdpi.com/2813-9909/2/3/10

7. “A Broken Heart and Windy Nights: Single Center Results of Inpatient Sleep Studies and Interventions in Hospitalized Heart Failure Patients”
by Justin N. Durland, Frank Hoyland, John Elliott Epps, Mathew J. Gregoski, Jacqueline Angles and
Gregory R. Jackson
Therapeutics 2025, 2(1), 1; https://doi.org/10.3390/therapeutics2010001
Available online: https://www.mdpi.com/2813-9909/2/1/1

8. “Novel 2D/3D Hybrid Organoid System for High-Throughput Drug Screening in iPSC Cardiomyocytes”
by Jordann Lewis, Basil Yaseen, Haodi Wu and Anita Saraf
Therapeutics 2025, 2(3), 11; https://doi.org/10.3390/therapeutics2030011
Available online: https://www.mdpi.com/2813-9909/2/3/11

9. “Patient and Healthcare Provider Perceptions of Handgrip Strength in an Internal Medicine Resident Clinic”
by Michaela Mastrud, Kirsten Juhl, Lindsey Dahl, Shabbir Haiderbhai, Peyton Lahr, Gunjan Manocha, Abbigail Olson, Jennifer Raum, David Theige and Ryan McGrath
Therapeutics 2025, 2(1), 4; https://doi.org/10.3390/therapeutics2010004
Available online: https://www.mdpi.com/2813-9909/2/1/4

10. “Safety and Clinical Impact of the Concomitant Use of Antifibrotic Drugs and Anticoagulants: A Single-Centre Retrospective Study”
by Alessandra Pagano, Matilde Bruni, Laura Tavanti, Francesco Pistelli, Davide Chimera, Laura Carrozzi, Alessandro Celi and Roberta Pancani
Therapeutics 2025, 2(2), 9; https://doi.org/10.3390/therapeutics2020009
Available online: https://www.mdpi.com/2813-9909/2/2/9

We invite you to read and submit relevant papers to the journal Therapeutics.

Therapeutics Editorial Office